ECSP088762A - Tratamiento del dolor - Google Patents

Tratamiento del dolor

Info

Publication number
ECSP088762A
ECSP088762A EC2008008762A ECSP088762A ECSP088762A EC SP088762 A ECSP088762 A EC SP088762A EC 2008008762 A EC2008008762 A EC 2008008762A EC SP088762 A ECSP088762 A EC SP088762A EC SP088762 A ECSP088762 A EC SP088762A
Authority
EC
Ecuador
Prior art keywords
pain
pain treatment
mammal
compound
formula
Prior art date
Application number
EC2008008762A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP088762A publication Critical patent/ECSP088762A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Esta invención proporciona un método para tratar el dolor en un mamífero que incluye administrar a un mamífero que necesita dicho tratamiento una cantidad efectiva para tratar el dolor de un compuesto de la Fórmula I: Io una sal farmacéuticamente aceptable del mismo, donde cada uno de R1, R2, R3, R4, R5, R6, n, y m es como se definió y describió en la presente. La presente invención también proporciona composiciones farmacéuticas para tratar el dolor que contienen una cantidad efectiva para tratar el dolor de un compuesto de Fórmula I.
EC2008008762A 2006-03-24 2008-09-23 Tratamiento del dolor ECSP088762A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78563306P 2006-03-24 2006-03-24

Publications (1)

Publication Number Publication Date
ECSP088762A true ECSP088762A (es) 2008-10-31

Family

ID=38332439

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008762A ECSP088762A (es) 2006-03-24 2008-09-23 Tratamiento del dolor

Country Status (16)

Country Link
US (1) US20070225277A1 (es)
EP (1) EP1998781A2 (es)
JP (1) JP2009531434A (es)
KR (1) KR20080110759A (es)
CN (1) CN101410118A (es)
AR (1) AR060089A1 (es)
AU (1) AU2007230997A1 (es)
BR (1) BRPI0709163A2 (es)
CA (1) CA2644656A1 (es)
EC (1) ECSP088762A (es)
IL (1) IL193748A0 (es)
MX (1) MX2008012092A (es)
PA (1) PA8720901A1 (es)
PE (1) PE20081192A1 (es)
TW (1) TW200806299A (es)
WO (1) WO2007112000A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
JP2009531435A (ja) * 2006-03-24 2009-09-03 ワイス うつ病の治療用の新規な治療組み合わせ
CA2644618A1 (en) * 2006-03-24 2007-10-04 Wyeth Methods for treating cognitive and other disorders
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
AU2009249071A1 (en) 2008-05-20 2009-11-26 Neurogesx, Inc. Hepatoprotectant acetaminophen mutual prodrugs
US8518933B2 (en) 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
US8546377B2 (en) * 2009-04-23 2013-10-01 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
EP2421870B1 (en) 2009-04-23 2016-03-09 AbbVie Inc. Modulators of 5-ht receptors and methods of use thereof
ES2423668T3 (es) * 2009-05-22 2013-09-23 Abbvie Inc. Moduladores de receptores 5-HT y métodos de uso de los mismos
WO2011071136A1 (ja) * 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
WO2011146089A1 (en) * 2010-05-21 2011-11-24 Abbott Laboratories Modulators of 5-ht receptors and methods of use thereof
US20140080813A1 (en) 2012-09-14 2014-03-20 AbbVie Deutschland GmbH & Co. KG Tricyclic quinoline and quinoxaline derivatives
BR112015005743A2 (pt) 2012-09-14 2017-07-04 Abbvie Deutschland derivados tricíclicos de quinoxalina e quinolina
US9573950B2 (en) 2014-03-14 2017-02-21 Abbvie Deutschland Gmbh & Co Kg Substituted [1,4]diazepino[6,7,1-ij]quinolines as serotonin 5-HT2C receptor modulators
US9540376B2 (en) 2014-03-14 2017-01-10 AbbVie Deutschland GmbH & Co. KG Hexahydrodiazepinoquinolines carrying a substituted alkyl radical
WO2016210431A1 (en) * 2015-06-26 2016-12-29 Wright State University Method of treating sepsis-induced myopathy
US20180339996A1 (en) 2015-11-25 2018-11-29 AbbVie Deutschland GmbH & Co. KG Hexahydropyrazinobenz- or -pyrido-oxazepines carrying an oxygen-containing substituent and use thereof in the treatment of 5-ht2c-dependent disorders
US20200039930A1 (en) 2017-03-21 2020-02-06 AbbVie Deutschland GmbH & Co. KG Proline amide compounds and their azetidine analogues carrying a specifically substituted benzyl radical

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3158619A (en) * 1962-06-14 1964-11-24 Searle & Co Certain sulfur-containing ortho-fused polycyclic pyrazole derivatives
US3235564A (en) * 1964-03-27 1966-02-15 Searle & Co Intermediates to certain sulfur-containing ortho-fused polycyclic pyrazole derivatives
US3335134A (en) * 1964-04-02 1967-08-08 Sandoz Ag Certain 3, 4-dihydrofluoreno[1, 9a, 9-e, f]1, 4-diazepin-3(2h)-ones
US3296252A (en) * 1964-04-02 1967-01-03 Sandoz Ag Tetracyclic diazepinone compounds
GB1120462A (en) * 1964-07-06 1968-07-17 Manuf Prod Pharma 3-alkoxy-2h-fluoreno[1,9-ef]-1,4-diazepine 1-oxides and derivatives thereof
US3417101A (en) * 1964-11-09 1968-12-17 American Home Prod Fused ring compounds
US3329676A (en) * 1964-11-09 1967-07-04 American Home Prod Fused 1, 4-diazepine ring systems
US3714149A (en) * 1969-11-03 1973-01-30 Upjohn Co Pyridobenzodiazepinones
US3914250A (en) * 1974-08-01 1975-10-21 American Home Prod 1,4-Diazepino{8 6,5,4-jk{9 carbazoles
US4880814A (en) * 1987-11-13 1989-11-14 Abbott Laboratories 7-cycloalkyl naphthyridines
GB8812636D0 (en) * 1988-05-27 1988-06-29 Glaxo Group Ltd Chemical compounds
EP0357417A1 (en) * 1988-09-01 1990-03-07 Glaxo Group Limited Lactam derivatives
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
ATE360617T1 (de) * 1994-06-15 2007-05-15 Otsuka Pharma Co Ltd Benzoheterocyclische verbindungen verwendbar als vasopressin- oder oxytocin-modulatoren
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
US5654334A (en) * 1995-06-23 1997-08-05 Oklahoma Medical Research Foundation Analgesic use of N-L-α-aspartyl-L-phenylalanine 1-methyl ester
TW359669B (en) * 1995-12-15 1999-06-01 Otsuka Pharma Co Ltd Benzazepine derivatives
CA2195697A1 (en) * 1996-02-02 1997-08-03 Masahumi Kitano Novel substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6194407B1 (en) * 1997-07-30 2001-02-27 American Home Products Corporation Tricyclic pyrido vasopressin agonists
US6031098A (en) * 1997-08-11 2000-02-29 California Institute Of Technology Detection and treatment of duplex polynucleotide damage
US6090803A (en) * 1998-07-24 2000-07-18 American Home Products Corporation Tricyclic vasopressin agonists
CO5210925A1 (es) * 1998-11-17 2002-10-30 Novartis Ag Derivados de diamino nitroguanidina tetrasustituidos
CA2374898C (en) * 1999-05-21 2009-12-08 Biovitrum Ab Pyrazinyl-piperazine compounds, their use and preparation
US6465467B1 (en) * 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
US6759405B2 (en) * 2000-11-03 2004-07-06 Wyeth Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AR031197A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta(b) diazepino(6,7,1-hi)indol
AR031198A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de ciclopenta(b)diazepino(6,7,1)indol
AR031201A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp /1,4/diazepino/6,7,1-jk/carbazoles y derivados
US6784172B2 (en) * 2000-11-03 2004-08-31 Wyeth Processes for preparation of cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
US6777407B2 (en) * 2000-11-03 2004-08-17 Wyeth Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AR031199A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados
AR031195A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta (b) (1,4) diazepino (6,7,1) diazepino (6,7,1-hi) indol
SE0004245D0 (sv) * 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
US6849619B2 (en) * 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
MXPA03005355A (es) * 2000-12-20 2004-05-27 Bristol Myers Squibb Co Pirroloquinolinas y piridoquinolinas sustituidas como agonistas y antagonistas de serotonina.
RU2003121304A (ru) * 2000-12-20 2005-01-27 Бристол-Маерс Сквибб Компани (Us) Замещенные пиридоиндолы в качестве агонистов и антагонистов серотонина
MXPA03007721A (es) * 2001-02-27 2004-11-12 Johnson & Johnson Compuesto de carbamato para su uso en el tratamiento del dolor.
US20020183395A1 (en) * 2001-04-04 2002-12-05 Wyeth Methods for treating hyperactive gastric motility
US6720316B2 (en) * 2001-08-06 2004-04-13 Pharmacia & Upjohn Company Therapeutic 5-HT ligand compounds
EP1436294A1 (en) * 2001-10-18 2004-07-14 PHARMACIA & UPJOHN COMPANY Tetracyclic azaindoles and -indolines having serotonin 5-ht2c activity
TWI312781B (en) * 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en) * 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TW200307682A (en) * 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
SE0201544D0 (sv) * 2002-05-17 2002-05-17 Biovitrum Ab Novel compounds and thier use
US20040235856A1 (en) * 2003-04-25 2004-11-25 Pfizer Inc Treatment of incontinence
AR051946A1 (es) * 2004-11-05 2007-02-21 Wyeth Corp Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina
PE20060939A1 (es) * 2004-11-05 2006-11-10 Wyeth Corp Metabolitos derivados de [1,4] diazepin[6,7,1-ij] quinolina y procedimiento de preparacion
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
AR056695A1 (es) * 2005-10-17 2007-10-17 Wyeth Corp Tetrahidroquinolinas, su sintesis e intermediarios
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
JP2009531435A (ja) * 2006-03-24 2009-09-03 ワイス うつ病の治療用の新規な治療組み合わせ
WO2007112073A2 (en) * 2006-03-24 2007-10-04 Wyeth Methods for modulating bladder function
CA2644618A1 (en) * 2006-03-24 2007-10-04 Wyeth Methods for treating cognitive and other disorders
MX2008012093A (es) * 2006-03-24 2008-10-03 Wyeth Corp Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos.
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.

Also Published As

Publication number Publication date
KR20080110759A (ko) 2008-12-19
BRPI0709163A2 (pt) 2011-06-28
AR060089A1 (es) 2008-05-21
JP2009531434A (ja) 2009-09-03
CA2644656A1 (en) 2007-10-04
MX2008012092A (es) 2008-10-03
PA8720901A1 (es) 2008-11-19
AU2007230997A1 (en) 2007-10-04
TW200806299A (en) 2008-02-01
PE20081192A1 (es) 2008-10-07
US20070225277A1 (en) 2007-09-27
WO2007112000A2 (en) 2007-10-04
WO2007112000A3 (en) 2008-01-17
EP1998781A2 (en) 2008-12-10
CN101410118A (zh) 2009-04-15
IL193748A0 (en) 2009-08-03

Similar Documents

Publication Publication Date Title
AR060089A1 (es) Tratamiento del dolor
ZA202109010B (en) Compounds and methods for the treatment of covid-19
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
EA201500265A1 (ru) Ингибиторы репликации вирусов гриппа
EA201290919A1 (ru) Индазольные соединения и их применение
EA200870254A1 (ru) Способ лечения воспалительных заболеваний
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
EA201490254A1 (ru) Комбинированное лечение гепатита с
CO6630082A2 (es) Tratamiento de lupus nefritis usando laquinimod
BR112014015482A2 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
BR112014006297A2 (pt) inibidores de n-[1-ciano-2-(fenil) etil]-2-azabiciclo [2.2.1] heptano-3-carboxamida de catepsina c, seus usos, e composição farmacêutica
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
NZ726366A (en) Syk inhibitors
AR101740A1 (es) Terapia de combinación y composiciones
EA201000603A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
BR112012033738A2 (pt) método para o tratamento de transtorno bipolar
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
AR077138A1 (es) Composiciones farmaceuticas utiles para tratar el vhc
EA201071043A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 и cx3cr1
BRPI0607536A2 (pt) tratamento de dor
EA201071352A1 (ru) Трициклические азотсодержащие соединения и их применение в качестве бактерицидных средств
BR112019005456A2 (pt) composição farmacêutica e método para tratamento de esteatose hepática não alcoólica
BR112012006070A2 (pt) composições e métodos para tratar distúrbios convulsivos.